SAN FRANCISCO - FibroGen, Inc. (NASDAQ:FGEN), a biopharmaceutical company, today announced the appointment of Deyaa Adib, M.D., as the new Senior Vice President & Chief Medical Officer, effective today. Dr. Adib brings nearly three decades of oncology development experience to FibroGen and will be responsible for overseeing the company's global clinical development activities.
Thane Wettig, CEO of FibroGen, expressed confidence in Dr. Adib's ability to accelerate the company's oncology pipeline and the development of new cancer therapies.
Wettig highlighted the significance of Dr. Adib's appointment as FibroGen prepares for important clinical milestones, including pivotal read-outs for pamrevlumab in pancreatic cancer, Phase 2 planning for FG-3246 in metastatic castration-resistant prostate cancer, as well as the filing of an Investigational New Drug (IND) application for their anti-Galectin-9 antibody and continued IND-enabling work for their anti-CCR8 antibody.
Dr. Adib's extensive background includes over 27 years in medical oncology within the biotechnology and pharmaceutical industries. His track record includes seven successful drug registrations for solid tumor and hematologic malignancy indications.
Before joining FibroGen, Dr. Adib served as Chief Medical Officer at Triumvira Immunologics Inc., where he led the transition of two cell therapy programs into clinical development. His previous roles include leadership positions at Rain Therapeutics, Blueprint Medicines (NASDAQ:BPMC), Baxalta, and ARIAD Pharmaceuticals, among others.
Dr. Adib has contributed to the development of several notable cancer therapies, including avapritinib for gastrointestinal stromal tumors and advanced systemic mastocytosis, as well as enzalutamide, which has significantly impacted the treatment of prostate cancer.
FibroGen is actively developing novel therapies for cancer, with pamrevlumab, an anti-CTGF fully human monoclonal antibody, in clinical trials for pancreatic cancer. The company also has roxadustat approved in various countries for anemia treatment in chronic kidney disease patients and is expanding its portfolio to include antibody-drug conjugate and immunoncology product candidates for solid tumors.
This announcement is based on a press release statement from FibroGen, Inc. Investors and stakeholders are advised that forward-looking statements involve risks and uncertainties, which may cause actual results to differ from those discussed in the press release. FibroGen does not undertake any obligation to update any forward-looking statement, except as required by law.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.